Sunday, December 11, 2016 5:20:30 PM
"We are about to reach our primary endpoint of our Registrational Phase III trial."
"Planning for topline data that is FDA approval ready then commercialization with partner and or buyout."
"Sell share at our terms there are buyers lined up."
"We are in a high stakes game of poker 10s of billions are at stake."
"It does NOT matter what exchange we are listed on for the plan forward."
"The MOS of our open arm which NO other company has EVER done is OVER 3 years!"
"......................."
Not my words folks....
I take notes whenever I speak with people that may affect my investment.
The only sentence that makes me nervous is number five, but I'm not selling very honest trustworthy people we are dealing with here.
Notice I left out comment six that's just me turning the screw on shorts but it is keeping me ALL IN."
Chris LaCoursiere
"Planning for topline data that is FDA approval ready then commercialization with partner and or buyout."
"Sell share at our terms there are buyers lined up."
"We are in a high stakes game of poker 10s of billions are at stake."
"It does NOT matter what exchange we are listed on for the plan forward."
"The MOS of our open arm which NO other company has EVER done is OVER 3 years!"
"......................."
Not my words folks....
I take notes whenever I speak with people that may affect my investment.
The only sentence that makes me nervous is number five, but I'm not selling very honest trustworthy people we are dealing with here.
Notice I left out comment six that's just me turning the screw on shorts but it is keeping me ALL IN."
Chris LaCoursiere
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
